KR102457475B1 - Cosmetic and functional food composition comprising caffeoylmalic acid having whitening and anti-photoaging activities - Google Patents
Cosmetic and functional food composition comprising caffeoylmalic acid having whitening and anti-photoaging activities Download PDFInfo
- Publication number
- KR102457475B1 KR102457475B1 KR1020200089496A KR20200089496A KR102457475B1 KR 102457475 B1 KR102457475 B1 KR 102457475B1 KR 1020200089496 A KR1020200089496 A KR 1020200089496A KR 20200089496 A KR20200089496 A KR 20200089496A KR 102457475 B1 KR102457475 B1 KR 102457475B1
- Authority
- KR
- South Korea
- Prior art keywords
- photoaging
- composition
- inhibition
- melanin
- skin whitening
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 125
- 230000002087 whitening effect Effects 0.000 title claims abstract description 49
- 239000002537 cosmetic Substances 0.000 title claims abstract description 48
- 206010051246 Photodermatosis Diseases 0.000 title claims abstract description 39
- BLANPKHHDVIMSA-UHFFFAOYSA-N 4-(1h-indol-5-yl)oxan-4-ol Chemical compound C=1C=C2NC=CC2=CC=1C1(O)CCOCC1 BLANPKHHDVIMSA-UHFFFAOYSA-N 0.000 title claims abstract description 25
- PMKQSEYPLQIEAY-UHFFFAOYSA-N trans-caffeoyl-L-malic acid Natural products OC(=O)CC(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 PMKQSEYPLQIEAY-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 235000013376 functional food Nutrition 0.000 title claims description 16
- 230000000694 effects Effects 0.000 title abstract description 11
- 210000003491 skin Anatomy 0.000 claims abstract description 63
- 230000008845 photoaging Effects 0.000 claims abstract description 38
- 230000005764 inhibitory process Effects 0.000 claims abstract description 31
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 27
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 16
- 230000005012 migration Effects 0.000 claims abstract description 16
- 238000013508 migration Methods 0.000 claims abstract description 16
- 230000008099 melanin synthesis Effects 0.000 claims abstract description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 74
- 210000004027 cell Anatomy 0.000 claims description 36
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 14
- 210000002752 melanocyte Anatomy 0.000 claims description 13
- 210000001339 epidermal cell Anatomy 0.000 claims description 11
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 10
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 10
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 10
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 10
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 10
- 235000005493 rutin Nutrition 0.000 claims description 10
- 229960004555 rutoside Drugs 0.000 claims description 10
- RLTNQOUWXZXZCS-VMMUDTPISA-N 2-(3,4-dihydroxyphenyl)-3-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]-3-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 RLTNQOUWXZXZCS-VMMUDTPISA-N 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 230000001629 suppression Effects 0.000 claims description 6
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 2
- 235000013305 food Nutrition 0.000 abstract description 28
- 230000006870 function Effects 0.000 abstract description 12
- 230000003796 beauty Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 238000009472 formulation Methods 0.000 description 20
- 210000002780 melanosome Anatomy 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 18
- 244000013123 dwarf bean Species 0.000 description 15
- 235000013361 beverage Nutrition 0.000 description 14
- 239000006071 cream Substances 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- -1 alpha-rhamnopyranosyl Chemical group 0.000 description 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 235000013350 formula milk Nutrition 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229960001285 quercetin Drugs 0.000 description 6
- 235000005875 quercetin Nutrition 0.000 description 6
- 102000006581 rab27 GTP-Binding Proteins Human genes 0.000 description 6
- 108010033990 rab27 GTP-Binding Proteins Proteins 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 229940069765 bean extract Drugs 0.000 description 5
- 235000015218 chewing gum Nutrition 0.000 description 5
- 229940112822 chewing gum Drugs 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 235000020712 soy bean extract Nutrition 0.000 description 5
- 240000003049 Canavalia gladiata Species 0.000 description 4
- 235000010518 Canavalia gladiata Nutrition 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000019219 chocolate Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 235000021331 green beans Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000007380 inflammaging Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- 102100037611 Lysophospholipase Human genes 0.000 description 3
- 108010058864 Phospholipases A2 Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000015895 biscuits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000004694 pigment cell Anatomy 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 235000013580 sausages Nutrition 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102100022874 Dexamethasone-induced Ras-related protein 1 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HILUWRPVFKJTAD-ZGHMGGRHSA-N GA21 Chemical compound O=C(O)[C@H]1[C@@H]2[C@]3(C(=O)O)C(=O)O[C@@]2([C@H]2[C@]41CC(=C)[C@@](O)(C4)CC2)CCC3 HILUWRPVFKJTAD-ZGHMGGRHSA-N 0.000 description 1
- UPCTWJNMQCQZPT-AODVQFRNSA-N Gibberellin A22 Chemical compound O=C(O)[C@H]1[C@@H]2[C@]3(CO)C(=O)O[C@@]2([C@H]2[C@]41CC(=C)[C@@](O)(C4)CC2)CC=C3 UPCTWJNMQCQZPT-AODVQFRNSA-N 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 101000620808 Homo sapiens Dexamethasone-induced Ras-related protein 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102100026158 Melanophilin Human genes 0.000 description 1
- 101710158003 Melanophilin Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000219098 Parthenocissus Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000004693 imidazolium salts Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000024181 negative regulation of developmental pigmentation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 카페오일말릭산을 포함하는 피부 미백 및 광노화 억제 화장료 조성물 및 미용식품에 관한 것이다. 본원에 따른 조성물은, 멜라닌 색소 생성 억제 및 각질세포로의 이동 억제를 통한 우수한 미백효능 및 광노화 억제 효과를 나타내며 천연물 유래로 부작용을 나타내지 않아 미백 및 광노화 억제 기능성을 지닌 화장료 조성물 및 미용식품으로 유용하게 이용될 수 있다. The present invention relates to a skin whitening and photoaging inhibitory cosmetic composition and cosmetic food containing caffeoyl malic acid. The composition according to the present application exhibits excellent whitening and photoaging inhibitory effects through inhibition of melanin production and migration to keratinocytes, and does not show side effects due to natural origin, so it is useful as a cosmetic composition and beauty food having whitening and photoaging inhibition functions can be used
Description
본 발명은 작두콩 추출물 함유하는 미백 및 광노화 억제 화장료 조성물 및 미용식품에 관한 것이다.The present invention relates to a whitening and photoaging inhibitory cosmetic composition and cosmetic food containing a soybean extract.
화장품 분야에서 동아시아 여성들 특히 한국, 일본, 중국의 여성들에게 가장 관심이 큰 분야중에 하나는 피부 미백과 노화 방지이다. In the cosmetic field, one of the fields of greatest interest to East Asian women, especially women from Korea, Japan and China, is skin whitening and anti-aging.
피부 미백과 관련하여 가장 중요한 요소는 피부 멜라닌 색소이다. 미백 기능성 화장품은 이미 피부에 침착된 멜라닌색소의 색을 엷게 하여 피부의 미백에 도움을 주는 기능을 가진다. 미백 기능성 화장품을 개발하기 위해 다양한 기전의 기능성 원료들이 개발되고 있으며, Arbutin, Kojic acid 등의 Tyrosinase inhibition 기전의 원료가 가장 대표적이며 이 외에 vitamin C 유도체들이 국내기능성 주성분으로 고시되고 있다. The most important factor in skin whitening is skin melanin pigment. Whitening functional cosmetics have the function of helping skin whitening by thinning the color of melanin pigment already deposited on the skin. In order to develop whitening functional cosmetics, functional raw materials with various mechanisms are being developed, and raw materials with a tyrosinase inhibition mechanism such as arbutin and kojic acid are the most representative.
멜라닌 또는 색소는 피부, 머리카락 및 눈의 색을 담당하고 피부에서 표피 멜라닌세포는 리소좀 (lysosome)과 관련된 특이 소기관인 멜라노좀 (melanosome)에서 멜라닌을 생성하게 된다 (Raposo and Marks, 2002, Traffic 3, 237-248). 멜라노좀은 명확히 정의된 순차적인 형태학적 단계를 통해 진행되는데 첫 번째 단계는 내부 신체 구조와 유사한 멜라닌이 없는 프리 멜라노좀이고, 두 번째 단계 멜라노좀은 intralumenal fibres (줄무늬)를 가진 길쭉한 구조이며, 세 번째 단계 멜라노좀은 멜라닌 침착을 보여주며 검은색 줄무늬로 이어지는 4 단계 멜라노좀은 멜라닌으로 가득 차 있게 된다 (Raposo et al., 2001, J. Cell Biol. 152, 809-824; Seiji et al., 1963, Nature 197, 1082-1084).Melanin or pigment is responsible for the color of skin, hair and eyes, and epidermal melanocytes in the skin produce melanin from melanosomes, which are specific organelles related to lysosomes (Raposo and Marks, 2002, Traffic 3, 237-248). Melanosomes progress through well-defined sequential morphological stages: the first stage is a free melanosome without melanin similar to the internal body structure, the second stage melanosome is an elongated structure with intralumenal fibres (stripes), three Stage 4 melanosomes show melanin deposition and stage 4 melanosomes leading to black streaks become filled with melanin (Raposo et al., 2001, J. Cell Biol. 152, 809-824; Seiji et al., 1963, Nature 197, 1082-1084).
표피 멜라닌 세포에서, 멜라노좀은 주변 각질 세포로 이동하기 전에 미세 소관 및 말초에 대한 액틴-의존적 수송을 거치게 되며 (Anister et al., 2002, Am. J. Hum. Genet. 71, 407-414; Marks et al., Nat. Rev. Mol. Cell Biol. 2, 738-748; Westbroek et al., 2001, Pigment Cell Res. 14, 320-327) 이때 Rab27a는 특정 세포 유형에서 리소좀 관련 소기관 (LRO)의 수송 및 엑소사이토시스를 제어하는 작은 GTPase Rab27 서브 패밀리의 구성인자로 작용하게 된다 (Izumi et al., 2003, Cell. Struct. Funct. 28, 465-474). Rab27a는 활성화된 GTP와의 결합 상태에서 멜라노좀 막에 위치하며 이때 멜라닌 세포-특이적 Rab27a effector인 melanophilin / Slac2-a에 의해 매개 된 액틴-의존적 MyosinVa 모터 단백질에 대한 수용체로서 작용하게 된다 (Fukuda et al., 2002, J. Biol. Chem. 277, 12432-12436; Strom et al., 2002, J. Biol. Chem. 277, 25423-25430; 2003; Wu et al., 2002, Mol. Biol. Cell 13, 1735-1749). 따라서 Rab27a의 발현억제는 Rab27a-melanophilin-myosinVa의 3중 복합체의 기능 상실을 초래하여, 정상적인 actin-dependent melanosome 수송 결함을 야기하고 말초 액틴에 의해 포획되어 피부색에 영향을 미치게 된다. In epidermal melanocytes, melanosomes undergo actin-dependent transport to microtubules and periphery before migrating to surrounding keratinocytes (Anister et al., 2002, Am. J. Hum. Genet. 71, 407-414; Marks et al., Nat. Rev. Mol. Cell Biol. 2, 738-748; Westbroek et al., 2001, Pigment Cell Res. 14, 320-327) wherein Rab27a is a lysosomal-associated organelle (LRO) in certain cell types. It acts as a member of the small GTPase Rab27 subfamily that controls transport and exocytosis (Izumi et al., 2003, Cell. Struct. Funct. 28, 465-474). Rab27a is located on the melanosome membrane in a state of binding to activated GTP, where it acts as a receptor for the actin-dependent MyosinVa motor protein mediated by melanophilin/Slac2-a, a melanocyte-specific Rab27a effector (Fukuda et al. ., 2002, J. Biol. Chem. 277, 12432-12436; Strom et al., 2002, J. Biol. Chem. 277, 25423-25430; 2003; Wu et al., 2002, Mol. Biol. Cell 13 , 1735-1749). Therefore, inhibition of Rab27a expression leads to loss of function of the triple complex of Rab27a-melanophilin-myosinVa, resulting in a defect in normal actin-dependent melanosome transport and entrapment by peripheral actin, which affects skin color.
타이로신 발현 억제 및 멜라노좀 이동 억제 기전의 원료가 미백 기능성 주성분으로 고시되고 있다. 멜라닌 생성을 억제하는 합성 화합물인 하이드로퀴논이 미백화장품의 주원료로 사용되다가 발암물질로 지정되면서 최근 인체 고유의 보호기능과 항상성을 유지시켜주는 자연유래 천연성분이 기능성 화장품 소재로 각광받고 있다. 알부틴, 닥나무추출물 등 천연소재로 대체되는 등 주요 기능성 화장품의 핵심원료들이 천연추출물 또는 천연유래성분으로 바뀌고 있는 추세이다. The raw material for the mechanism of inhibiting tyrosine expression and melanosome migration is announced as a whitening functional main ingredient. Hydroquinone, a synthetic compound that inhibits melanin production, was used as a main ingredient in whitening cosmetics and was designated as a carcinogen. The core ingredients of major functional cosmetics, such as arbutin and mulberry extract, are being replaced with natural ingredients.
대한민국 공개특허공보 제2013-0001027호 (2013-01-03 공개)는 산초나물 추출물을 포함하는 미백용 화장료 조성물 및 그 제조방법을 개시한다. Korean Patent Application Laid-Open No. 2013-0001027 (published on 01/03/2013) discloses a cosmetic composition for whitening containing an extract of wild herbs and a method for preparing the same.
그러나 천연물에는 아직도 규명되지 않은 다양한 성분이 존재하며, 새로운 물질을 발견하고 그 용도를 크게 확대할 수 있는 가능성이 있다. 따라서 이러한 멜라노좀 생성 및 이동과 관련된 근본적인 기전에 영향을 미치는 천연물질의 발굴이 필요하다.However, there are still unidentified various components in natural products, and there is a possibility of discovering new substances and greatly expanding their uses. Therefore, it is necessary to discover natural substances that affect the fundamental mechanisms related to the generation and movement of melanosomes.
본원은 독성이 없으면서도 효과적으로 멜라노좀 이동 및 생성 저해 및 광노화를 억제할 수 있는 근원적인 천연물질 유래의 미백 및 광노화 억제 화장품 조성물 및 식품을 제공하고자 한다.An object of the present application is to provide a whitening and photoaging inhibitory cosmetic composition and food derived from a natural substance that can effectively inhibit melanosome migration and generation and photoaging without toxicity.
한 양태에서 본원은 카페오일말릭산을 포함하는 피부 미백 및 광노화 억제용 화장료 조성물을 제공한다.In one aspect, the present application provides a cosmetic composition for skin whitening and photoaging inhibition comprising caffeoyl malic acid.
본원에 따른 조성물은 퀘르세틴 3-O-beta-(2(G)-O-beta-xylopyranosyl- 6(G)-O-alpha-rhamnopyranosyl)glucopyranoside) 또는 루틴 (2-(3,4- dihydroxyphenyl)-5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyloxy]-4H-chromen-4-one) 중 하나 이상을 추가로 포함할 수 있다.The composition according to the present application is quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O-alpha-rhamnopyranosyl)glucopyranoside) or rutin (2-(3,4-dihydroxyphenyl)- 5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyanosyloxy]-4H-chromen-4-one) may be further included.
본원에 따른 화장료 조성물에 의한 피부미백은 피부 표피 세포를 구성하는 멜라닌형성 세포에서 생성된 멜라닌의 각질형성 세포로의 이동 억제; 및 멜라닌형성 세포에서 멜라닌 생성 억제 기전에 의한 것으로, 멜라닌의 피부 침착을 효과적으로 억제하여 피부 미백에 효과적으로 사용될 수 있다. Skin whitening by the cosmetic composition according to the present application inhibits the movement of melanin produced in melanocytes constituting the epidermal cells of the skin to keratinocytes; And it is due to the mechanism of inhibiting melanin production in melanin-forming cells, and it can be effectively used for skin whitening by effectively inhibiting the skin deposition of melanin.
또한 일 구현예에서 본원에 따른 조성물에 의한 멜라닌의 각질세포로의 이동 억제는 이에 관여하는 Rab27A 및 MyosinVa의 발현 억제에 의한 것으로, 이는 멜라닌의 피부 침착을 효과적으로 억제하여 피부 미백에 효과적으로 사용될 수 있음을 나타낸다. In addition, in one embodiment, the inhibition of the migration of melanin into keratinocytes by the composition according to the present application is due to inhibition of the expression of Rab27A and MyosinVa involved therein, which effectively inhibits the deposition of melanin on the skin and thus can be effectively used for skin whitening. indicates.
또한 본원에 따른 조성물은 광노화 억제는 COX-2 (cyclooxygenase-2) 발현 억제에 의한 것으로, 세포의 분자 수준에서 광노화를 효과적으로 억제할 수 있다.In addition, the composition according to the present application inhibits photoaging by inhibiting the expression of cyclooxygenase-2 (COX-2), and can effectively inhibit photoaging at the molecular level of cells.
다른 양태에서 본원은 또한 카페오일말릭산을 포함하는, 피부 미백 및 광노화 개선용 기능성 식품 조성물을 제공한다. In another aspect, the present application also provides a functional food composition for improving skin whitening and photoaging, comprising caffeoyl malic acid.
일 구현예에서 상기 기능성 식품 조성물은 퀘르세틴 3-O-beta-(2(G)-O- beta-xylopyranosyl-6(G)-O-alpha-rhamnopyranosyl)glucopyranoside) 또는 루틴 (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyloxy]-4H-chromen-4-one) 중 하나 이상을 추가로 포함한다. In one embodiment, the functional food composition is quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O-alpha-rhamnopyranosyl)glucopyranoside) or rutin (2-(3,4 -dihydroxyphenyl)-5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyanosyloxy]-4H-chromen-4-one).
본원에 따른 식품 조성물에 의한 피부미백은 피부 표피 세포를 구성하는 멜라닌형성 세포에서 생성된 멜라닌의 각질형성 세포로의 이동 억제; 및 멜라닌형성 세포에서 멜라닌 생성 억제 기전에 의한 것으로, 멜라닌의 피부 침착을 효과적으로 억제하여 피부 미백에 효과적으로 사용될 수 있다. Skin whitening by the food composition according to the present application inhibits the movement of melanin produced in melanocytes constituting the epidermal cells of the skin to the keratinocytes; And it is due to the mechanism of inhibiting melanin production in melanin-forming cells, and it can be effectively used for skin whitening by effectively inhibiting the skin deposition of melanin.
또한 일 구현예에서 본원에 따른 식품 조성물에 의한 멜라닌의 각질세포로의 이동 억제는 이에 관여하는 Rab27A 및 MyosinVa의 발현 억제에 의한 것으로, 이는 멜라닌의 피부 침착을 효과적으로 억제하여 피부 미백에 효과적으로 사용될 수 있음을 나타낸다. In addition, in one embodiment, the inhibition of the migration of melanin into keratinocytes by the food composition according to the present application is due to the inhibition of the expression of Rab27A and MyosinVa involved therein, which effectively inhibits the deposition of melanin on the skin and thus can be effectively used for skin whitening indicates
또한 본원에 따른 식품 조성물에 의한 광노화 억제는 COX-2 (cyclooxygenase-2) 발현 억제에 의한 것으로, 세포의 분자 수준에서 광노화를 효과적으로 억제할 수 있다.In addition, the inhibition of photoaging by the food composition according to the present application is by inhibition of COX-2 (cyclooxygenase-2) expression, and can effectively inhibit photoaging at the molecular level of cells.
도 1은 본원에 따른 추출물이 유래된 작두콩의 사진 및 작두콩잎에서 추출된 의 3종 지표성분 (caffeoylmalic acid (#1), Quercetin 3-O-beta-(2(G)-O- beta-xylopyranosyl-6(G)-O-alpha-rhamnopyranosyl)glucopyranoside (#2) 및 rutin (#3))을 나타내는 화학 구조식이다.
도 2는 본원의 한 구현예에 따른 작두콩으로부터 분리동정된 카페오일말릭산의 멜라노좀 이동과 관련된 인자인 Rab27A 발현 억제효능을 나타내는 결과이다.
도 3은 본원의 한 구현예에 따른 작두콩으로부터 분리동정된 카페오일말릭산의 멜라닌 이동과 관련된 인자인 MyosinVa 발현 억제효능을 나타내는 결과이다.
도 4는 본원의 한 구현예에 따른 작두콩잎 추출물로부터 분리 동정된 카페오일말릭산 (caffeoylmalic acid)의 멜라닌형성 억제효능을 나타내는 결과이다.
도 5는 본원의 한 구현예에 따른 작두콩잎 추출물로부터 분리 동정된 caffeoylmalic acid (#1), Quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl-6 (G)-O-alpha-rhamnopyranosyl)glucopyranoside (#2) 및 rutin (#3)의 자외선 조사로 유발된 COX-2 발현에 미치는 영향을 나타내는 결과이다.
도 6a는 종래의 연구되고 있는 멜라노좀 이동, 전달 및 Turnover를 나타내는 모식도이다 (Hume et al., 2001, The J. of Cell Biol. 152; 795-808).
도 6b는 본원의 작두콩 추출물에서 분리동정된 caffeoylmalic acid가 관여하는 멜라노좀의 표피세포로의 이동에 관여하는 마커인자인 MyosinVa, Rab27A에 대한 발현억제 기전을 나타내는 모식도이다 (Briganti, S., et al., (2003). Pigment Cell Res. 16, 101-110.).1 is a photograph of green beans from which an extract according to the present application is derived, and three indicator components (caffeoylmalic acid (#1), Quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl Chemical structural formula representing -6(G)-O-alpha-rhamnopyranosyl)glucopyranoside (#2) and rutin (#3)).
2 is a result showing the effect of inhibiting the expression of Rab27A, a factor related to melanosome migration of caffeoyl malic acid isolated and identified from green beans according to one embodiment of the present application.
3 is a result showing the effect of inhibiting the expression of MyosinVa, a factor related to the melanin movement of caffeoyl malic acid isolated and identified from green beans according to one embodiment of the present application.
Figure 4 is a result showing the melanin formation inhibitory effect of caffeoylmalic acid (caffeoylmalic acid) isolated and identified from the green bean leaf extract according to one embodiment of the present application.
5 is a caffeoylmalic acid (#1), Quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl-6 (G)-O- Results showing the effect of alpha-rhamnopyranosyl)glucopyranoside (#2) and rutin (#3) on COX-2 expression induced by UV irradiation.
Figure 6a is a schematic diagram showing melanosome migration, transfer, and turnover that has been previously studied (Hume et al., 2001, The J. of Cell Biol. 152; 795-808).
Figure 6b is a schematic diagram showing the mechanism of suppression of the expression of MyosinVa, Rab27A, which are marker factors involved in the migration of melanosomes involving caffeoylmalic acid isolated and identified from the bean extract of the present application to epidermal cells (Briganti, S., et al. ., (2003) Pigment Cell Res. 16, 101-110.).
본원은 카페오일말릭산 (Caffeoylmalic acid)이 독성이 없으면서도 멜라노좀 이동 및 생성 억제 및 광노화를 억제할 수 있어 효과적인 미백 및 광노화 억제 화장품 조성물 및 미용 식품으로 활용될 수 있다는 발견에 근거한 것이다.The present application is based on the discovery that caffeoylmalic acid can be used as an effective whitening and photoaging inhibiting cosmetic composition and cosmetic food because it can inhibit melanosome migration and generation and photoaging while being nontoxic.
이에 한 양태에서 본원은 카페오일말릭산을 유효성분으로 포함하는 피부 미백 및/또는 광노화 억제용 화장료 조성물에 관한 것이다. Accordingly, in one aspect, the present application relates to a cosmetic composition for skin whitening and/or photoaging inhibition comprising caffeoyl malic acid as an active ingredient.
일 구현예에서 상기 카페오일말릭산은 작두콩 (Canavalia gladiata)에서 분리동정된 것이다.In one embodiment, the caffeo oil malic acid is isolated and identified from soybeans ( Canavalia gladiata ).
작두콩 (Canavalia gladiata)은 콩과의 한해살이 덩굴성 식물로 6-7월에 꽃이 피고 8-10월에 열매인 꼬투리를 맺고 늦가을에 열매가 익는다. 동남아시아 열대지방이 원산지이며, 열매는 활모양이며 그 모양이 작두와 같아 작두콩 혹은 도두 (刀豆)라 부른다. 도 1은 작두콩의 사진 및 작두콩잎의 3종 지표성분을 나타내는 화학 구조식이다. 작두콩에는 urease, hemaglutinine, canavanine, canavalia gibberellin I과 II 등의 약용성분을 함유하고 있으며, 민간요법에서는 축농증, 치질, 종기 등 화농성 염증을 치료하는 특효약으로 사용되어 왔다. 이러한 작두콩의 우수한 기능성을 바탕으로 중국에서 작두콩을 발효시켜 "개발한 진화 851" 구복액이라는 음료가 건강보조제로 국내에 소개된 적이 있고, 일본에서는 작두콩에 질경이, 율무, 산치자, 예덕나무를 배합해 만든 건강차인 "도두파워"가 제품으로 판매되기도 하였다. 전 세계적으로 작두콩 (Canavalia gladiata)으로 부터 보고된 연구내용은 65편으로 나타나나 어디에도 본원 내용인 멜라닌 이동의 저해를 통한 미백효능 및 광화 억제에 관한 연구내용은 알려진바 없다.Green bean ( Canavalia gladiata ) is an annual creeper plant in the legume family, which flowers in June-July, produces fruit pods in August-October, and ripens in late autumn. It is native to the tropical regions of Southeast Asia, and the fruit is in the shape of a bow and the shape is similar to that of a bean sprout. 1 is a chemical structural formula showing a photograph of green beans and three index components of a green bean leaf. Soybeans contain medicinal ingredients such as urease, hemaglutinine, canavanine, canavalia gibberellin I and II, and in folk remedies, it has been used as a special drug to treat purulent inflammation such as sinusitis, hemorrhoids, and boils. Based on these excellent functions, a drink called “Evolution 851,” which was developed by fermenting soybeans in China, was introduced as a health supplement in Korea. The health tea "Dodu Power" made was also sold as a product. Although there are 65 studies reported from Canavalia gladiata worldwide, there are no studies on whitening efficacy and mineralization inhibition through the inhibition of melanin migration, which is the content of this application.
일 구현예에서 본원에 따른 조성물은 하기 유효성분 중 하나 이상을 추가로 포함할 수 있다: 퀘르세틴 3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O-alpha- rhamnopyranosyl)glucopyranoside) 또는 루틴 (2-(3,4-dihydroxyphenyl)- 5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyloxy]-4H- chromen-4-one). In one embodiment, the composition according to the present application may further include one or more of the following active ingredients: quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O-alpha -rhamnopyranosyl)glucopyranoside) or rutin (2-(3,4-dihydroxyphenyl)- 5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyloxy]-4H-chromn- 4-one).
피부 표피세포는 각질형성 세포 및 멜라닌 형성 세포를 포함하고 있는데 (도 6a 참조), 본원에 분리된 유효성분 특히 카페오일말릭산은 멜라닌형성 세포에서 멜라닌의 생성 억제는 물론 생성된 멜라닌의 각질형성 세포로의 이동을 억제한다. The skin epidermal cells include keratinocytes and melanin-forming cells (see FIG. 6a), and the active ingredient, particularly caffeoyl malic acid, isolated herein inhibits the production of melanin in the melanin-forming cells, as well as the keratinocytes of the produced melanin. inhibit the movement of
이에 일 구현예에서 피부 미백은 멜라닌형성 세포에서 멜라닌의 합성 억제에 의한 것이다. Accordingly, in one embodiment, skin whitening is by inhibition of the synthesis of melanin in melanocytes.
다른 구현예에서 본원에 따른 조성물에 의한 피부 미백은 표피 세포를 구성하는 멜라닌형성 세포에서 생성된 멜라닌의 각질형성 세포로의 이동의 억제에 의한 것이다. In another embodiment, skin whitening by the composition according to the present application is by inhibition of the migration of melanin produced in melanogenic cells constituting epidermal cells to keratinocytes.
또 다른 구현예에서 피부미백은 멜라닌의 각질형성 세포로의 이동에 관여하는 유전자인 Rab27A (Ras-related protein) (Jordens et al., 2006, Pigment Cell Res. 19; 412-423) 및 Myosin Va (Yao et al., Scientific Reports | 5:10874 | DOI: 10.1038/srep10874 1) 발현 억제에 의한 것이다. 특히 본원에 따른 카페오일말릭산은 멜라노좀의 이동과 관련된 마커인 Rab27A 및 MyosinVa의 발현을 억제하였으며 (도 2 및 도 3 참조), 이는 피부색소화 과정의 I, II, III 단계 (도 6a 및 도 6b 참조) 중 멜라닌 생합성 이후 멜라노좀의 표피세포로의 이동에 영향을 미치는 것이다. In another embodiment, skin whitening is a gene involved in the movement of melanin to keratinocytes, Rab27A (Ras-related protein) (Jordens et al ., 2006, Pigment Cell Res. 19; 412-423) and Myosin Va ( Yao et al ., Scientific Reports | 5:10874 | DOI: 10.1038/srep10874 1) by suppression of expression. In particular, caffeoyl malic acid according to the present application inhibited the expression of Rab27A and MyosinVa, which are markers related to the migration of melanosomes (see FIGS. 2 and 3 ), which are steps I, II, and III of the skin pigmentation process ( FIGS. 6A and 6B ). See), which affects the movement of melanosomes to epidermal cells after melanin biosynthesis.
또한 본원에 따른 카페오일말릭산은 멜라닌의 합성을 억제하는 것으로 나타나 (도 4 참조), 본원에 따른 조성물은 표피세포에서 멜라닌의 합성 및 이동을 억제하여 피부 미백에 효과적으로 사용될 수 있다. In addition, caffeoyl malic acid according to the present application is shown to inhibit the synthesis of melanin (see FIG. 4 ), and the composition according to the present application can be effectively used for skin whitening by inhibiting the synthesis and migration of melanin in epidermal cells.
또한 본원에 따른 유효성분을 포함하는 조성물은 피부 광노화 억제 효능을 나타낸다. 현재 피부 노화와 관련하여 "Inflammatory"와 "aging"의 합성어로 "Infl ammaging" 이라는 새로운 개념이 대두되고 있다. 이는 UV와 같은 광스트레스에 의해 유발된 염증 반응에 의한 노화와 관련이 있다고 추정되고 있는 것이다. UVB에 의해 유도되는 염증반응은 prostaglandin이나 leukotriene 등과 같은 염증 매개체 (inflammatory mediator)의 생성을 수반하며, UVB 노출 조건에서 이들 eicosanoid의 생성은 phospholipase A2 (PLA2)의 발현 또는 활성 증가와 밀접한 관련이 있는 것으로 알려져 왔으나 최근의 연구보고에 의하면 prostaglandin 생성에 있어 PLA2의 하위 단계인 COX-2 (Cyclooxygenase-2)의 발현 역시 자외선 조사에 의해 야기되는 프로스타글란딘 생성 증가에 매우 중요한 역할을 하는 것으로 보고되었다 (Lee et al., 2012, Exp. Mol. Med. 44; 536-544; Afnan et al., 2016, Exp. Dermatol. 25; 440-446). 따라서 COX-2의 발현 억제는 광노화 억제와 관련되어 있다. 본원에서는 본원에 따른 작두콩 추출물이 이러한 Inflammaging 타겟 중 하나인 COX-2의 발현을 억제하는 것으로 나타났으며 (도 5 참조), 이는 본원에 따른 작두콩 추출물의 광노화 억제효능을 나타내는 것이다.In addition, the composition comprising the active ingredient according to the present application exhibits skin photoaging inhibitory efficacy. A new concept of “Inflammaging” is emerging as a compound word of “Inflammatory” and “aging” in relation to skin aging. This is presumed to be related to aging due to the inflammatory response induced by light stress such as UV. The UVB-induced inflammatory response involves the production of inflammatory mediators such as prostaglandin and leukotriene, and the production of these eicosanoids under UVB exposure conditions is closely related to the increase in the expression or activity of phospholipase A2 (PLA2). However, according to a recent study report, it was reported that the expression of COX-2 (Cyclooxygenase-2), a sub-step of PLA2 in prostaglandin production, also plays a very important role in the increase in prostaglandin production caused by UV irradiation (Lee et al . ., 2012, Exp. Mol. Med. 44; 536-544; Afnan et al ., 2016, Exp. Dermatol. 25; 440-446) . Therefore, inhibition of COX-2 expression is related to inhibition of photoaging. Herein, it was shown that the pea extract according to the present application inhibits the expression of COX-2, which is one of these inflammaging targets (see FIG. 5 ), indicating the photoaging inhibitory effect of the pea extract according to the present application.
이에 본원에 따른 조성물은 피부미백 및/또는 광노화 억제/개선에 유효하게 사용될 수 있다.Accordingly, the composition according to the present application can be effectively used for skin whitening and/or photoaging inhibition/improvement.
본원에서 "피부 미백" 이란 자외선, 스트레스, 호르몬 분비 이상 및 임신 등과 같은 외부 환경 변화에 의해 피부 내에 색소의 생성이 과하게 일어나 발생하는 피부색의 변화 또는 색소 침착을 억제하는 것으로, 상술한 각종 요인에 의해 발생하는 거뭇거뭇한 피부, 기미, 주근깨, 다크서클을 개선 또는 방지 또는 예방하는 효과, 피부의 투명감을 증가시키는 효과, 피부의 칙칙함을 개선하여 윤기 및 팽팽함을 증가시키는 효과를 포함한다. As used herein, "skin whitening" refers to suppression of changes in skin color or pigmentation caused by excessive production of pigments in the skin due to external environmental changes such as ultraviolet rays, stress, abnormal hormone secretion and pregnancy, etc. It includes an effect of improving or preventing or preventing darkening of the skin, freckles, freckles, and dark circles, an effect of increasing the translucency of the skin, and an effect of improving the dullness of the skin to increase the gloss and tightness.
일반적으로 피부의 색소 침착은 자외선에 의한 자극 또는 호르몬 불균형으로 인해 멜라노사이트가 자극되고 여기에서 생합성된 멜라닌 색소의 피부 침착이 주 원인이다. 따라서 표피 세포를 구성하는 멜라닌 생합성 세포인 멜로노사이트에서 표피 세포를 구성하는 다른 세포인 각질형성 세포로의 멜라닌의 이동을 억제할 수 있는 본원에 따른 조성물은 상술한 미백이외에 색소 침착의 억제를 필요로 하는 다양한 용도로 사용될 수 있다.In general, the pigmentation of the skin is stimulated by ultraviolet rays or hormonal imbalance, and melanocytes are stimulated, and the skin deposition of melanin pigment biosynthesized here is the main cause. Therefore, the composition according to the present application capable of inhibiting the movement of melanin from melonocytes, which are melanin biosynthetic cells constituting epidermal cells, to keratinocytes, which are other cells constituting epidermal cells, requires inhibition of pigmentation in addition to the above-mentioned whitening. It can be used for a variety of purposes.
광노화는 피부 노화를 유발하는 원인 중 하나로, 자외선을 포함하는 빛에 의한 피부 노화를 의미한다. 피부 노화는 크게 자연노화와 광노화의 두 가지 경우로 나누어 볼 수 있으며, 피부의 주름으로 특징된다. 피부의 주름은 세포재생 능력의 저하로 인해 콜라겐이나 엘라스틴 같은 탄력섬유가 감소하거나 활성산소에 의해 과산화지질이 생성되거나 생체 구성물질의 산화에 따른 변성, 과도한 근육운동에 의한 피로 등이 원인으로 알려져 있다. 본원에 따른 작두콩 추출물을 앞서 언급한 바와 같이 Inflammaging 타겟 중 하나인 COX-2의 발현을 억제하여 광노화에 의한 피부 노화 억제 및/또는 개선에 유용하게 사용될 수 있다. Photoaging is one of the causes of skin aging and refers to skin aging caused by light including ultraviolet rays. Skin aging can be broadly divided into two cases, natural aging and photoaging, and is characterized by wrinkles on the skin. Wrinkles of the skin are known to be caused by a decrease in elastic fibers such as collagen or elastin due to a decrease in cell regeneration ability, the generation of lipid peroxide by free radicals, degeneration due to the oxidation of biomaterials, and fatigue due to excessive muscle exercise. . As mentioned above, the green soybean extract according to the present application may be usefully used to suppress and/or improve skin aging due to photoaging by inhibiting the expression of COX-2, one of the inflammaging targets.
본원에서 사용된 용어 화장료 조성물은 인체를 청결미화하여 용모를 밝게 변화시키거나 피부, 모발의 건강을 유지 또는 증진하기 위하여 인체에 사용되는 물품을 의미하며, 인체에 대한 작용이 경미한 것을 말한다. 통상적인 의미로서, 로션, 크림, 오일, 세정용 제품 및 기능성 화장품을 모두 포함한다. 기능성 화장품이란 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 화장품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 화장품군이나 화장품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 화장품을 포함한다. As used herein, the term cosmetic composition refers to an article used in the human body to brighten the appearance by cleaning and beautify the human body, or to maintain or promote health of skin and hair, and has a slight action on the human body. In a conventional sense, it includes lotions, creams, oils, cleaning products and functional cosmetics. Functional cosmetics refers to a group of cosmetics that have added added value to act and express the functions of the cosmetics for a specific purpose using physical, biochemical, and bioengineering methods, etc. Includes cosmetics designed and processed to sufficiently express functions in the living body.
본원에 따른 화장료 조성물 또는 화장품은, 예를 들면, 크림, 로션, 앰플, 스킨, 에센스, 비누 등으로 제공될 수 있으며, 다른 측면에서 기초 화장품 조성물 (화장수, 크림, 에센스, 클렌징 폼 및 클렌징 워터와 같은 세안제, 팩, 보디오일), 색조 화장품 조성물 (화운데이션, 립스틱, 마스카라, 메이크업 베이스), 또는 마스크 또는 팩의 형태로 제조될 수 있다.The cosmetic composition or cosmetic according to the present application may be provided as, for example, a cream, lotion, ampoule, skin, essence, soap, etc., and in another aspect, the basic cosmetic composition (lotion, cream, essence, cleansing foam and cleansing water such as face wash, pack, body oil), color cosmetic composition (foundation, lipstick, mascara, makeup base), or in the form of a mask or pack.
본원에 따른 화장료 조성물 또는 화장품이 적용될 수 있는 부위는 신체의 특정 지방 조직에 한정되는 것은 아니며 예를 들면, 색소 침착 억제 또는 미백이 필요한 다양한 부위의 피부, 특히 얼굴, 팔, 다리 등에 적용될 수 있다. 적용되는 부위에 다양한 투여 경로, 예를 들면 전신 또는 국소, 특히 국소 투여, 경피, 또는 주사, 특히 경피 경로로 투여될 수 있다.The portion to which the cosmetic composition or cosmetics according to the present application can be applied is not limited to a specific adipose tissue of the body, and for example, it can be applied to the skin of various areas requiring pigmentation suppression or whitening, particularly the face, arms, legs, and the like. Administration may be carried out at the site of application by various routes of administration, for example systemic or topical, particularly topical, transdermal, or injection, particularly transdermal.
본원에 따른 화장료 조성물은 지시된 비율로 필수 성분으로서 본원의 작두콩 추출물 또는 이로부터 분리된 1종 이상의 유효성분을 포함하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 화장품, 예를 들면 크림의 경우, 식물성 오일, 유화제, 증점제, 향료, 물, 산화방지제, 및 UV 흡수제를 포함 할 수 있다.The cosmetic composition according to the present application is not particularly limited in other ingredients except for including the bean extract of the present application or at least one active ingredient isolated therefrom as an essential ingredient in the indicated ratio, and in the case of conventional cosmetics, for example, a cream, vegetable oils, emulsifiers, thickeners, fragrances, water, antioxidants, and UV absorbers.
본원에 따른 조성물에 포함되는 추출물의 함량은 목적하는 제품의 구체적 용도 또는 제형 등에 따라 달라질 수 있으나, 전체 조성물 중에 약 0.001 내지 약 50 중량% 로 포함될 수 있으나, 이 범위를 벋어나는 것을 제외하는 것은 아니다. The content of the extract included in the composition according to the present application may vary depending on the specific use or formulation of the desired product, but may be included in an amount of about 0.001 to about 50% by weight in the total composition, but does not exclude those outside this range .
본원에 따른 화장료 조성물은 작두콩 추출물 및/또는 이로부터 분리된 1종 이상의 유효성분에 부가하여 항산화제, 안정화제, 용해화제, 비타민, 안료 및/또는 향료와 같은 통상적인 보조제 및 담체를 포함할 수 있다. The cosmetic composition according to the present disclosure may include conventional adjuvants and carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments and/or fragrances in addition to the soybean extract and/or one or more active ingredients isolated therefrom. have.
본원의 화장료 조성물은 공액리놀레산, 리놀레산, 감마-리놀레산, 알파-리놀레산을 포함하는 불포화지방산 또는 프로필렌 글리콜을 포함하는 수용성 기제 물질을 포함할 수 있다. The cosmetic composition of the present disclosure may include an unsaturated fatty acid including conjugated linoleic acid, linoleic acid, gamma-linoleic acid, alpha-linoleic acid, or a water-soluble base material including propylene glycol.
또한 본원의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 마스크, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.In addition, the cosmetic composition of the present application may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a mask, a pack, a spray, or a powder.
본원 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present application is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide is used as a carrier component. can be
본원 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present application is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propellants such as propane/butane or dimethyl ether.
본원에 따른 화장료 조성물은 화장품용으로/피부학적으로 허용가능한 담체를 추가로 포함할 수 있다. "화장품용으로/피부학적으로 허용가능한"은 지나친 독성, 불상용성, 불안정성, 자극, 알러지 반응 등이 없이 조직 (예를 들어, 피부 또는 모발)과 접촉하여 사용하기에 적합함을 의미한다.The cosmetic composition according to the present disclosure may further comprise a cosmetically/dermatologically acceptable carrier. "Cosmetic/dermatologically acceptable" means suitable for use in contact with tissue (eg, skin or hair) without undue toxicity, incompatibility, instability, irritation, allergic reaction, etc.
본원 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 사용될 수 있다. When the formulation of the present composition is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 fatty acid esters of ,3-butylglycol, glycerol aliphatic esters, polyethylene glycol or sorbitan may be used.
본원 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 사용될 수 있다.When the formulation of the present composition is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, and microcrystals Adult cellulose, aluminum metahydroxide, bentonite, agar, or tracanth may be used.
본원 조성물의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리움 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다. 바람직한 투여 유형에 따르면, 본 발명의 조성물은 최소한 하나의 약학적으로 허용되는 부형제, 특히 피부학적으로 허용 가능한 부형제를 포함할 수 있다. When the formulation of the composition of the present application is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolium derivative, methyltaurate, sarcosinate, fatty acid amide ether as carrier components Sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester may be used. According to a preferred mode of administration, the composition of the present invention may comprise at least one pharmaceutically acceptable excipient, in particular a dermatologically acceptable excipient.
또한, 상기 각 제형의 피부용 조성물에 있어서, 상기한 필수 성분 이외의 다른 성분들은 기타 피부용 조성물 또는 사용목적 등에 따라 당업자가 어려움 없이 선정하여 배합할 수 있다.In addition, in the composition for skin of each formulation, other components other than the above-mentioned essential components can be selected and formulated without difficulty by those skilled in the art according to other skin compositions or purposes of use.
본 발명의 조성물은 독성 및 부작용은 거의 없으므로 예방 목적으로 장기간 사용시에도 안심하고 사용할 수 있다. Since the composition of the present invention has almost no toxicity and side effects, it can be safely used even for long-term use for prophylactic purposes.
이에 따라, 상기 본원에 따른 작두콩 추출물은 식품의 주, 부원료 및 식품 첨가제로서 또는 미백 및/또는 광노화 개선 기능성 식품 등의 건강기능식품 소재로 활용 가능하다. Accordingly, the green bean extract according to the present application can be used as a main, auxiliary material, and food additive of food, or as a material for health functional food such as whitening and/or photoaging improvement functional food.
본 명세서에서 사용된 용어 "식품" 이란 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미로서, 식품, 식품 첨가제, 기능성식품 및 음료를 모두 포함하는 의도이다.As used herein, the term "food" means a natural product or processed product containing one or more nutrients, and preferably means a state that can be directly eaten through a certain processing process, In a sense, it is intended to include all foods, food additives, functional foods and beverages.
본 명세서에서 사용된 용어 "기능성식품" 이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미하며, 특히 "건강기능식품"을 포함한다.As used herein, the term "functional food" refers to a food group or food composition that has added value to act and express the function of the food for a specific purpose using physical, biochemical, and bioengineering methods, etc. , refers to foods designed and processed to sufficiently express body control functions related to disease prevention and recovery, etc. to the living body, and in particular includes "health functional foods".
본 명세서에서 사용된 용어 "건강보조식품" 이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 가공한 식품으로서, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 건강보조의 목적으로 특정성분을 원료로 하거나 식품원료에 들어있는 성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말한다. As used herein, the term "health supplement" refers to a food manufactured and processed using raw materials or ingredients having useful functions in the human body, and is useful for health purposes such as regulating nutrients or physiological action with respect to the structure and function of the human body. It refers to food manufactured and processed by extracting, concentrating, refining, or mixing ingredients contained in food raw materials or using specific ingredients as raw materials for the purpose of health supplements to obtain an effect.
상기 기능성식품 및 건강보조식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 더욱 포함할 수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.The functional food and health supplement may further include a food supplementary additive that is pharmaceutically acceptable, and may further include an appropriate carrier, excipient and diluent commonly used in the manufacture of functional food.
본원에 따른 작두콩 추출물 및/또는 이로부터 분리된 1종 이상의 유효성분을 첨가할 수 있는 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 기능성 식품 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품 (예, 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류 (예, 라면류, 국수류 등), 건강보조식품, 조미식품 (예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류 (예, 스넥류), 유가공품 (예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품 (각종 김치류, 장아찌 등), 음료 (예, 과실,채소류 음료, 두유류, 발효 음료류 등), 천연조미료 (예, 라면 스프 등)을 포함하나 이에 한정되지 않는다. 상기 식품, 음료 또는 식품첨가제는 통상의 제조방법으로 제조될 수 있다.Foods to which the green bean extract according to the present application and/or one or more active ingredients separated therefrom can be added include, for example, various foods, beverages, gum, tea, vitamin complexes, functional foods, and the like. In addition, in the present invention, food includes special nutritional food (eg, formula milk, infant food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (eg, ramen, noodles, etc.), health supplements, seasoned foods ( Ex, soy sauce, soybean paste, red pepper paste, mixed soy sauce, etc.), sauces, sweets (eg snacks), dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various kimchi, pickles, etc.), beverages ( Examples include, but are not limited to, fruit and vegetable beverages, soy milk, fermented beverages, etc.) and natural seasonings (eg, ramen soup, etc.). The food, beverage or food additive may be prepared by a conventional manufacturing method.
일 구현예에서는 기능성 음료로 제조되며, 기능성 음료란 음료에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 음료의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 음료 군이나 음료 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 음료를 의미하며, 특히 피부 탄력 향상, 콜라겐 합성 촉진을 위한 음료를 의미한다.In one embodiment, it is manufactured as a functional beverage, and a functional beverage is a beverage group or beverage composition with added value added so that the beverage can act and express the function of the beverage for a specific purpose using physical, biochemical, or bioengineering methods, etc. It refers to a beverage designed and processed to sufficiently express the body control functions related to defense rhythm control, disease prevention and recovery, etc. to the living body, and in particular, it refers to a beverage for improving skin elasticity and promoting collagen synthesis.
본원의 식품 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분을 독립적으로 또는 조합하여 사용할 수 있다.The food composition of the present application contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. These components may be used independently or in combination.
이하, 본 발명의 이해를 돕기 위해서 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐 본 발명이 하기의 실시예에 한정되는 것은 아니다.Hereinafter, examples are presented to help the understanding of the present invention. However, the following examples are only provided for easier understanding of the present invention, and the present invention is not limited thereto.
실 시 예Example
실시예 1. 작두콩잎 (Example 1. Green bean leaf ( Canavalia gladiataCanavalia gladiata ) 추출물로부터 지표성분 화합물의 분리 동정 ) Separation and identification of the indicator compound from the extract
작두콩잎 추출물로부터 활성성분 화합물을 분리하기위해 추출물을 제조하고 용매 분획물을 제조 하였다. 구체적으로 건조된 작두콩잎 10kg을 30% (W/W) 에탄올 수용액 (1→30)에 60℃에서 5시간 추출한 후, 250 메쉬 여과포로 여과하고 0.3 ㎛ 필터로 여과하였다. 이후 여과액을 감압농축하여 조추출물을 제조하였다. 용매 분획물을 제조하기 위해 조추출물은 증류수로 현탁시킨 후 동량의 에틸아세테이트 용매를 가하여 2회 반복 추출하였다. 그 후 증류수층을 회수하고 감압 농축하여 작두콩잎 증류수 가용 분획물을 수득하였다. 작두콩잎 증류수 가용 추출물은 HP-20 resin column chromaytography를 Water:EtOH (Water 100% → EtOH 30%)의 조건으로 실시하여 추출물을 크게 3개의 분획 (CG-1 ~ CG-3)으로 나누어 수득하였다. CG-1 분획에서 단일 성분을 정제하였으며 분광학적 방법을 이용하여 구조를 동정한 결과 하기 화학식 1의 구조를 갖는 Caffeoylmalic acid (2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxybutanedioic acid) (#1)인 것을 확인하였다. In order to isolate the active ingredient compound from the soybean leaf extract, an extract was prepared and a solvent fraction was prepared. Specifically, 10 kg of dried green bean leaves were extracted in 30% (W/W) aqueous ethanol solution (1→30) at 60° C. for 5 hours, then filtered with a 250 mesh filter cloth and filtered with a 0.3 μm filter. Then, the filtrate was concentrated under reduced pressure to prepare a crude extract. In order to prepare a solvent fraction, the crude extract was suspended in distilled water, and the same amount of ethyl acetate solvent was added thereto, followed by extraction twice. Thereafter, the distilled water layer was recovered and concentrated under reduced pressure to obtain a distilled water soluble fraction of green bean leaves. The distilled water soluble extract of green bean leaf was obtained by performing HP-20 resin column chromatography under the conditions of Water:EtOH (
[화학식 1][Formula 1]
이어, CG-1 분획으로부터 단일 성분을 분리하였고 LC-MS 측정 결과, m/z 743, 611, 465, 303의 ion peak가 확인되었다. m/z 743 모분자로 가지며 m/z 611, m/z 303 을 갖는 것으로 보아 qercetin 배당체임을 알 수 있었고, 모분자로부터 m/z 132가 소실되는 단편이온으로 xylose (m/z 132) 결합이 있음을 확인하였다. 그리고 m/z 611 로부터 rhamnose (m/z 146)가 제거된 ion 패턴을 확인하였다. 위 결과를 토대로 화학식 2의 구조를 갖는 Quercetin [3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O-alpha-rhamnopyranosyl)glucopyranoside](#2)로 동정하였다.Then, a single component was separated from the CG-1 fraction, and as a result of LC-MS measurement, ion peaks of m/z 743, 611, 465, and 303 were confirmed. It has m/z 743 as a parent molecule and has m/z 611 and m/z 303, indicating that it is a qercetin glycoside. confirmed that there is. And the ion pattern from which rhamnose (m/z 146) was removed was confirmed from m/z 611. Based on the above results, it was identified as Quercetin [3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O-alpha-rhamnopyranosyl)glucopyranoside](#2) having the structure of
[M+Na]+ 765; [M+H]+ 743; [M+H-xyl]+ 611; [M+H-Rham-xyl]+ 465; [quercetin aglycone]+ 303;[M+Na] + 765; [M+H] + 743; [M+H-xyl] + 611; [M+H-Rham-xyl] + 465; [quercetin aglycone] + 303;
[화학식 2][Formula 2]
이어 CG-2 분획으로부터 단일 성분을 분리하였고, 하기 표 1에 기재된 조건의 고성능액체크로마토그래피를 이용하여 Sigma-aldrich 에서 구입한 Rutin 표준품과 비교 분석하여 1차적으로 확인하였다. 그리고 LC-MS 측정 결과, m/z 611을 모분자로 가지며 m/z 303을 갖는 것을 확인하여 Quercetin 배당체임을 확인하였고 rhamnose (m/z 146)가 제거되고 glucose (m/z 162)가 제거되는 동일한 ion 패턴을 확인하였다. 위 결과를 토대로 화학식 3의 구조를 갖는 Rutin [2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyloxy]-4H-chromen-4-one] (#3) 으로 동정하였다. Then, a single component was isolated from the CG-2 fraction, and it was first confirmed by comparative analysis with a rutin standard purchased from Sigma-aldrich using high-performance liquid chromatography under the conditions shown in Table 1 below. And as a result of LC-MS measurement, m/z 611 as a parent molecule and m/z 303 were confirmed to be Quercetin glycosides, and rhamnose (m/z 146) and glucose (m/z 162) were removed. The same ion pattern was confirmed. Based on the above results, Rutin [2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyanosyloxy]- 4H-chromen-4-one] (#3).
[M+Na]+ 633; [M+H]+ 611; [M+H-Rham]+ 465; [quercetin aglycone]+ 303;[M+Na] + 633; [M+H] + 611; [M+H-Rham] + 465; [quercetin aglycone] + 303;
[표 1][Table 1]
[화학식 3][Formula 3]
실시예 2. 멜라닌 이동의 타겟 인자인 Rab27A 및 MyosinVa 발현 억제능 분석Example 2. Analysis of ability to inhibit expression of Rab27A and MyosinVa, which are target factors of melanin migration
마우스 멜라노사이트인 멜란-에이 세포에서의 멜라닌 이동 주요 마커인자인 Rab27A 발현량을 확인하기 위하여 문헌에 기재된 방법을 참조하여 하기와 같이 실험을 수행하였다 (Hong JY et al. (2011) J Nat Prod 74:2012-8). In order to confirm the expression level of Rab27A, a major marker of melanin migration in melanocytes, which are mouse melanocytes, an experiment was performed as follows with reference to the method described in the literature (Hong JY et al. (2011) J Nat Prod 74). :2012-8).
10% FBS가 포함된 RPMI 배지로 100 mm 배양접시에 1ⅹ106 개의 농도로 주입하고, 37℃, 5% CO2 조건에서 24시간을 배양한 후 인산 완충 생리식염수 (PBS)로 2회 세척하였다. 부착된 세포를 회수하여 PBS로 2회 세척한 후 끓고 있는 2ⅹ 시료 loading buffer (250 mM Tris-HCl (pH 6.8), 4% SDS, 10% glycerol, 0.006% bromophenol blue, 2% β-mercaptoethanol, 50 mM sodium fluoride와 5 mM sodium orthovanadate)를 넣어 세포를 파쇄시키고 이를 100℃에서 5분간 유지하였다. 식힌 후 20℃에서 보관하였고 사용 직전에 37℃에서 녹여 단백질 정량 및 전기영동에 이용하였다. 80 μg의 단백질을 5 ~ 12 % SDS-polyacrylamide gel (#456-1036, Bio-rad, Hercules, CA)을 이용하여 138 V에서 2시간 동안 전기영동을 수행하였다. 분리된 단백질을 PVDF 멤브레인 (membrane, ISEQ15150, Millipore, Bedford, MA)으로 100 V에서 1시간 동안 옮긴 후 PBST로 2회 세척하고 blocking buffer (5% non-fat dry milk in PBS containing 0.1% Tween-20 (PBST))에 주입하여 상온에서 1시간 동안 진탕기에서 배양하였다. 그 다음 PBST로 5분간 3회씩 세척한 후 해당 단일항체를 PBST로 3% 비지방 건조 우유 (non-fat dry milk)로 희석하여 멤브레인 (membrane)과 함께 4℃에서 18시간 반응시켰다. 멤브레인 [Membrane, ISEQ 1S150, Millipore, Bedford, MA)을 PBST로 5분간 3회 세척한 후 HRP (horseradish peroxidase)-결합 이차항체를 PBST로 3% 탈지분유로 1:1,000 ~ 1:2,000의 비율로 희석하여 멤브레인 (membrane)과 함께 상온에서 3 ~ 4시간 반응시켰다. 이후 PBST로 5분간 3회 세척한 후 화학발광 (chemiluminescent) 시약 (LabFrontier, Suwon, Korea)으로 처리하였다. LAS-3000 (Fuji Film Corp., Japan)에서 Rab27A 및 β-actin의 단백질 발현 정도를 확인하였다. 그 결과는 도 2에 기재되어 있다. 작두콩으로부터 분리동정된 caffeoylmalic acid에 의하여 농도의존적으로 Rab27A 단백질 발현이 억제되는 것을 확인하였다.RPMI medium containing 10% FBS was injected at a concentration of 1× 10 6 in a 100 mm culture dish, incubated for 24 hours at 37° C. and 5% CO 2 conditions, and washed twice with phosphate buffered saline (PBS). After recovering the adherent cells and washing twice with PBS, boiling 2x sample loading buffer (250 mM Tris-HCl (pH 6.8), 4% SDS, 10% glycerol, 0.006% bromophenol blue, 2% β-mercaptoethanol, 50 mM sodium fluoride and 5 mM sodium orthovanadate) were added to disrupt the cells and maintained at 100° C. for 5 minutes. After cooling, it was stored at 20°C, and immediately before use, it was dissolved at 37°C and used for protein quantification and electrophoresis. 80 μg of protein was electrophoresed at 138 V for 2 hours using 5 ~ 12 % SDS-polyacrylamide gel (#456-1036, Bio-rad, Hercules, CA). The separated protein was transferred to a PVDF membrane (membrane, ISEQ15150, Millipore, Bedford, MA) at 100 V for 1 hour, washed twice with PBST, and a blocking buffer (5% non-fat dry milk in PBS containing 0.1% Tween-20) (PBST)) and incubated on a shaker at room temperature for 1 hour. Then, after washing 3 times for 5 minutes with PBST, the single antibody was diluted with PBST with 3% non-fat dry milk and reacted with a membrane at 4°C for 18 hours. The membrane [Membrane, ISEQ 1S150, Millipore, Bedford, MA) was washed 3 times for 5 minutes with PBST, and then the HRP (horseradish peroxidase)-conjugated secondary antibody was used with PBST and 3% skim milk powder at a ratio of 1:1,000 to 1:2,000. It was diluted and reacted with a membrane at room temperature for 3 to 4 hours. After washing 3 times for 5 minutes with PBST, it was treated with a chemiluminescent reagent (LabFrontier, Suwon, Korea). The protein expression levels of Rab27A and β-actin were confirmed in LAS-3000 (Fuji Film Corp., Japan). The results are shown in FIG. 2 . It was confirmed that the expression of Rab27A protein was inhibited in a concentration-dependent manner by caffeoylmalic acid isolated and identified from soybeans.
또한 멜란-에이 세포주를 confocal dish에 2 x 104 cells/ml plating 하여 24시간 동안 세포를 증식시킨 후 PBS로 세척하여 세포에 있는 FBS을 완전히 제거하고 4% paraformaldehyde로 15분간 고정한 후 0.1% Triton X-100을 이용하여 5분간 permeabilization을 수행하였다. 이어서 1% BSA를 이용하여 30분간 상온에서 blocking을 수행한 후 4℃에서 1차 antibody 용액에 인큐베이션 (incubation)한 상태로 하룻밤을 수행하였다. Fluorescence-conjugated 2차 antibody를 상온에서 2시간 인큐베이션한 후에 DAPI (0.5 μg/ml)를 반대염색을 시켜준 후 콘포칼 현미경을 이용하여 이미지를 촬영하였다. 그 결과는 도 3에 기재되어 있다. 작두콩 추출물로부터 분리 동정된 카페오일말릭산 20, 40, 60 μM 처리에 따라 농도의존적으로 MyosinVa 단백질 발현이 감소되는 것을 확인하였다. In addition, the melan-A cell line was plated with 2 x 10 4 cells/ml in a confocal dish, proliferated for 24 hours, washed with PBS to completely remove FBS from the cells, fixed with 4% paraformaldehyde for 15 minutes, and then 0.1% Triton X Permeabilization was performed for 5 minutes using -100. Then, blocking was performed at room temperature for 30 minutes using 1% BSA, and then incubated in the primary antibody solution at 4° C. overnight. After incubating the fluorescence-conjugated secondary antibody at room temperature for 2 hours, counterstaining with DAPI (0.5 μg/ml) was performed, and then images were taken using a confocal microscope. The results are shown in FIG. 3 . It was confirmed that MyosinVa protein expression was decreased in a concentration-dependent manner according to the treatment with 20, 40, and 60 μM of caffeoyl malic acid isolated and identified from the soybean extract.
실시예 3. 피부 미백 효능 평가Example 3. Evaluation of skin whitening efficacy
추가적으로, 동물세포주에서 타이로시나제 저해 효능 측정은 작두콩 추출물을 처리한 마우스의 멜라노사이트 세포주인 멜란-에이 세포의 멜라닌 생성 억제 활성을 측정함으로써 이뤄졌다. 멜라닌 정량은 호소이 등 (Hosoi J et al., Cancer Res., 45(4), pp1474-1478, 1985)의 방법을 변형하여 사용하였다. Additionally, tyrosinase inhibitory efficacy in animal cell lines was measured by measuring the melanogenesis inhibitory activity of melan-A cells, a melanocyte cell line of mice treated with green bean extract. Melanin quantification was used by modifying the method of Hosoi et al. (Hosoi J et al., Cancer Res., 45(4), pp1474-1478, 1985).
마우스의 멜라노사이트 (melanocyte)인 멜란-에이 (Melan-a) 세포를 6-웰 플레이트 (6-well plate)에 3×104 세포수/well로 분주하고 48시간 배양하여 세포를 부착시킨 후, caffeoylmalic acid를 최종농도 20 μM이 되도록 처리하고 3 ~ 5일 동안 배양하였다. 배양세포를 염화칼슘 (CaCl2), 염화마그네슘 (MgCl2))이 들어있지 않은 인산염완충액 (DPBS; Dulbecco's Phosphated Buffered Saline)으로 2회 세척하고 트립신 (trypsin, Gibco, USA)을 처리하여 세포를 분리하여 각 군당 동일한 수의 세포를 수집하였다. 세포침전물을 염화칼슘 (CaCl2)), 염화마그네슘 (MgCl2)이 들어있지 않은 인산염완충액 (DPBS; Dulbecco's Phosphated Buffered Saline)으로 세척하고 100 ㎕의 10% 디메틸술폭시화물 (DMSO)이 첨가된 1 노르말농도 (N)의 수산화나트륨 (NaOH) 용액으로 현탁한 후 60℃에서 30분간 처리하고 475 nm에서 흡광도를 측정하여 합성 멜라닌으로 작성된 표준곡선으로부터 멜라닌양을 환산하여 저해율을 나타낸 바 도 4에 나타난 바와 같이 caffeoylmalic acid를 20 μM 첨가시 통계적으로 유의성을 나타내며 (*P < 0.05) 24.4% 멜라닌 합성을 저해하는 것으로 나타났다.Melan-a cells, which are melanocytes from mice, were dispensed in a 6-well plate at 3×10 4 cells/well and cultured for 48 hours to attach the cells, Caffeoylmalic acid was treated to a final concentration of 20 μM and cultured for 3 to 5 days. The cultured cells were washed twice with phosphate buffer (DPBS; Dulbecco's Phosphated Buffered Saline) that does not contain calcium chloride (CaCl 2 ), magnesium chloride (MgCl 2 )) and treated with trypsin (trypsin, Gibco, USA) to separate the cells. Equal number of cells were collected for each group. The cell precipitate was washed with a phosphate buffer (DPBS; Dulbecco's Phosphated Buffered Saline) that does not contain calcium chloride (CaCl 2 )) and magnesium chloride (MgCl 2 ), and 100 μl of 10% dimethyl sulfoxide (DMSO) was added to 1 normal After being suspended in a sodium hydroxide (NaOH) solution of concentration (N), treated at 60 ° C. for 30 minutes, absorbance was measured at 475 nm, and the amount of melanin was converted from a standard curve made of synthetic melanin to show the inhibition rate as shown in FIG. Similarly, when 20 μM of caffeoylmalic acid was added, it was statistically significant (*P < 0.05) and inhibited 24.4% of melanin synthesis.
따라서 작두콩잎 추출물로부터 분리동정된 카페오일말릭산은 멜라노좀 이동성 뿐 만 아니라 멜라닌 생합성도 억제함으로서 미백효능을 지닌 화장료 조성물로서 활용 가능성이 매우 높은 것으로 나타났다.Therefore, it was found that caffeoyl malic acid isolated and identified from bean leaf extract has a very high potential for use as a cosmetic composition with whitening effect by inhibiting melanosome biosynthesis as well as melanosome mobility.
실시예 4. 광노화 억제효능 평가 (Inflammaging 타겟 연구) Example 4. Evaluation of photoaging inhibitory efficacy (Inflammaging target study)
본원의 작두콩 추출물의 광노화 억제효능을 평가하기 위해 사람의 각질세포인 HaCaT 세포주를 30 배양접시에 2.2×105 cells/ml plating 하여 24시간 동안 세포를 증식시킨 후 cell confluency가 90% 정도 도달했을때 PBS로 3번 세척하여 세포에 있는 FBS을 완전히 제거하였다. 이후 작두콩잎 추출물로부터 분리동정된 #1 (caffeoylmalic acid), #2 (Quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl- 6(G)-O-alpha-rhamnopyranosyl)glucopyranoside, #3 (rutin)가 각각 20 μM가 함유된 배지 (0.5 % FBS, 1 % AA in colorless DMEM)를 원래 배지량의 1/4 용량만 넣어 15 mJ/cm2 UVB 조사후 남은 배지를 넣어 37℃ 5% CO2 incubator에서 6시간 처리하였다. 그 결과는 도 5에 기재되어 있다. 대표적인 항염 효소계인 COX-2 단백질 발현량이 대조구에 비해 UV 조사시 현저하게 증가하였으며 20μg/ml 농도에서 작두콩잎 추출물로부터 분리 동정된 #1, 2, 및 3 물질로부터 광노화 억제효능을 분석한 결과 COX-2 발현이 현저하게 억제되는 것을 확인하였다. In order to evaluate the photoaging inhibitory effect of the green soybean extract of the present application, a HaCaT cell line, a human keratinocyte, was used for 30 After plating 2.2×10 5 cells/ml on a culture dish, the cells were proliferated for 24 hours, and when the cell confluency reached about 90%, the cells were washed 3 times with PBS to completely remove FBS from the cells. #1 (caffeoylmalic acid), #2 (Quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O-alpha-rhamnopyranosyl)glucopyranoside, Add only 1/4 volume of the original medium (0.5% FBS, 1% AA in colorless DMEM) containing 20 μM of #3 (rutin), 15 mJ/cm 2 Add the remaining medium after UVB irradiation at 37
이하, 본 발명의 제형예로서 크림 조성물, 마사지크림 조성물, 로션 조성물, 스킨로션 조성물, 에센스 조성물, 팩 조성물 및 클렌징폼 조성물을 예시하고 있으나, 본 발명의 화장품 조성물을 포함하는 제형은 이에 한정되는 것은 아니다. Hereinafter, a cream composition, a massage cream composition, a lotion composition, a skin lotion composition, an essence composition, a pack composition, and a cleansing foam composition are exemplified as formulation examples of the present invention, but the formulation including the cosmetic composition of the present invention is limited thereto not.
제형예 1. 크림 조성물Formulation Example 1. Cream composition
하기 표에 기재된 조성 및 함량 (중량%)으로 유상과 수상을 각각 75℃로 가열 혼합한 후 실온으로 냉각한다.After heating and mixing the oil phase and the aqueous phase at 75° C., respectively, with the composition and content (% by weight) shown in the table below, the mixture is cooled to room temperature.
제형예 2. 마사지 크림 조성물Formulation Example 2. Massage Cream Composition
하기 표에 기재된 조성 및 함량 (중량%)으로 유상과 수상을 각각 75℃로 가열 용해 혼합한 후 실온으로 냉각한다.The oil phase and the aqueous phase are each heated to 75° C. to dissolve and mix with the composition and content (% by weight) shown in the table below, and then cooled to room temperature.
제형예 3. 로션 조성물Formulation Example 3. Lotion composition
하기 표에 기재된 조성 및 함량 (중량%)으로 유상과 수상을 각각 75℃로 가열 혼합 유화한 후 실온으로 냉각한다.After emulsifying the oil phase and the aqueous phase at 75° C., respectively, with the composition and content (% by weight) shown in the table below, the mixture is cooled to room temperature.
제형예 4. 스킨로션 조성물Formulation Example 4. Skin lotion composition
하기 표에 기재된 조성 및 함량 (중량%)으로 수상과 에탄올상을 각각 제조 혼합한 후 여과한다.The aqueous phase and the ethanol phase are prepared and mixed with the composition and content (% by weight) shown in the table below, and then filtered.
제형예 5. 에센스 조성물Formulation Example 5. Essence composition
하기 표에 기재된 조성 및 함량 (중량%)으로 수상과 에탄올상을 각각 제조 혼합한 후 여과한다.The aqueous phase and the ethanol phase are prepared and mixed with the composition and content (% by weight) shown in the table below, and then filtered.
제형예 6. 팩 조성물Formulation Example 6. Pack composition
하기 표에 기재된 조성 및 함량 (중량%)으로 수상과 에탄올상을 각각 분산 용해하여 혼합시킨 후 실온으로 냉각한다.Dispersing and dissolving the aqueous phase and the ethanol phase, respectively, with the composition and content (wt%) described in the table below, mixing, and then cooling to room temperature.
제형예 7. 클렌징폼 조성물Formulation Example 7. Cleansing Foam Composition
하기 표에 기재된 조성 및 함량 (중량%)으로 수상과 오일상을 각각 분산 용해하여 혼합 검화한 후 실온으로 냉각한다.After dispersing and dissolving each of the aqueous phase and the oil phase with the composition and content (% by weight) shown in the table below, mixing and saponification, the mixture is cooled to room temperature.
또한 본 발명의 미용식품으로서의 제형예로서 츄잉껌, 캔디, 비스켓, 아이스크림, 소세지, 초콜렛, 일반 음료 및 미백 프로바이오틱스 유산균 음료 제형을 예시하고 있으나, 본 발명의 미용식품 조성물을 포함하는 제형은 이에 한정되는 것은 아니다.In addition, as formulation examples of the cosmetic food of the present invention, chewing gum, candy, biscuit, ice cream, sausage, chocolate, general beverage and whitening probiotic lactic acid bacteria beverage formulation are exemplified, but the formulation containing the cosmetic food composition of the present invention is limited thereto not.
제조예 1. 츄잉껌 (A)의 제조Preparation Example 1. Preparation of Chewing Gum (A)
하기 표의 조성 및 함량과 통상적인 방법으로 츄잉껌을 제조하였다.Chewing gum was prepared in the usual manner with the composition and content shown in the table below.
제조예 2. 츄잉껌 (B)의 제조Preparation Example 2. Preparation of Chewing Gum (B)
하기 표의 조성 및 함량과 통상적인 방법으로 츄잉껌을 제조하였다.Chewing gum was prepared in the usual manner with the composition and content shown in the table below.
제조예 3. 캔디 (A)의 제조Preparation Example 3. Preparation of Candy (A)
하기 표의 조성 및 함량과 통상적인 방법으로 캔디를 제조하였다.Candy was prepared according to the composition and content shown in the table below and the conventional method.
제조예 4. 캔디 (B)의 제조Preparation Example 4. Preparation of Candy (B)
하기 표의 조성 및 함량과 통상적인 방법으로 캔디를 제조하였다.Candy was prepared according to the composition and content shown in the table below and the conventional method.
제조예 5. 비스켓의 제조
하기 표의 조성 및 함량과 통상적인 방법으로 비스켓을 제조하였다.Biscuits were prepared according to the composition and content in the table below and the conventional method.
제조예 6. 아이스크림의 제조Preparation Example 6. Preparation of ice cream
하기 표의 조성 및 함량과 통상적인 방법으로 아이스크림을 제조하였다.Ice cream was prepared in a conventional manner with the composition and content shown in the table below.
제조예 7. 소세지의 제조Preparation Example 7. Preparation of Sausage
하기 표의 조성 및 함량과 통상적인 방법으로 소세지를 제조하였다.Sausages were prepared in the usual manner with the composition and content of the table below.
제조예 8. 초콜렛의 제조Production Example 8. Production of chocolate
하기 표의 조성 및 함량과 통상적인 방법으로 초콜렛을 제조하였다.Chocolate was prepared in a conventional manner with the composition and content of the table below.
제조예 9. 건강식품의 제조Preparation 9. Preparation of health food
하기 표의 조성 및 함량과 통상적인 방법으로 건강식품을 제조하였다.Health food was prepared in the usual manner with the composition and content of the table below.
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixture is a composition that is relatively suitable for health food in a preferred embodiment, but the mixing ratio may be arbitrarily modified. , to prepare granules, and can be used in the manufacture of health food compositions according to a conventional method.
제조예 10. 건강음료의 제조Preparation Example 10. Preparation of health drinks
하기 표의 조성 및 함량과 통상적인 방법으로 건강음료를 제조하였다.A health drink was prepared in the usual manner with the composition and content of the table below.
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above ingredients according to a conventional health drink manufacturing method, stirring and heating at 85° C. for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2L container, sealed and sterilized, and then refrigerated. used in the manufacture of health beverage compositions of
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is prepared by mixing ingredients suitable for relatively favorite beverages in a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and national preferences such as demand class, demanding country, and use.
Claims (10)
A cosmetic composition for skin whitening and photoaging inhibition comprising caffeoyl malic acid.
상기 조성물은 퀘르세틴 3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O- alpha-rhamnopyranosyl)glucopyranoside) 또는 루틴 (2-(3,4-dihydroxyphenyl)- 5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyloxy]- 4H-chromen-4-one) 중 하나 이상을 추가로 포함하는 것인, 피부 미백 및 광노화 억제용 화장료 조성물.
The method of claim 1,
The composition comprises quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O-alpha-rhamnopyranosyl)glucopyranoside) or rutin (2-(3,4-dihydroxyphenyl)-5, 7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyanosyloxy]-4H-chromen-4-one) which further comprises one or more of, skin whitening and photoaging inhibition cosmetic composition for use.
상기 피부미백은 피부 표피 세포를 구성하는 멜라닌형성 세포에서 생성된 멜라닌의 각질형성 세포로의 이동 억제; 및 멜라닌형성 세포에서 멜라닌 생성 억제에 의한 것인, 피부 미백 및 광노화 억제용 화장료 조성물.
The method of claim 1,
The skin whitening inhibits the movement of melanin generated in melanin forming cells constituting the epidermal cells of the skin to the keratinocytes; And by inhibiting melanin production in melanocytes, a cosmetic composition for skin whitening and photoaging inhibition.
상기 멜라닌의 각질세포로의 이동 억제는 이에 관여하는 Rab27A 및 MyosinVa의 발현 억제에 의한 것인, 피부 미백 및 광노화 억제용 화장료 조성물.
4. The method of claim 3,
The inhibition of the migration of melanin into keratinocytes is by suppression of the expression of Rab27A and MyosinVa involved therein, a cosmetic composition for skin whitening and photoaging inhibition.
상기 광노화 억제는 COX-2 (cyclooxygenase-2) 발현 억제에 의한 것인, 피부 미백 및 광노화 억제용 화장료 조성물.
3. The method according to claim 1 or 2,
The photoaging inhibition is by inhibition of COX-2 (cyclooxygenase-2) expression, a cosmetic composition for skin whitening and inhibition of photoaging.
A functional food composition for skin whitening and photoaging improvement, comprising caffeoyl malic acid.
상기 조성물은 퀘르세틴 3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)- O-alpha-rhamnopyranosyl)glucopyranoside) 또는 루틴 (2-(3,4-dihydroxyphenyl)- 5,7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyloxy]- 4H-chromen-4-one) 중 하나 이상을 추가로 포함하는 것인, 피부 미백 및 광노화 개선용 기능성 식품 조성물.
7. The method of claim 6,
The composition comprises quercetin 3-O-beta-(2(G)-O-beta-xylopyranosyl-6(G)-O-alpha-rhamnopyranosyl)glucopyranoside) or rutin (2-(3,4-dihydroxyphenyl)-5, 7-dihydroxy-3-[α-L-rhamnopyranosyl-(1→6)-β-D-glucopyanosyloxy]-4H-chromen-4-one) to further include one or more of, skin whitening and photoaging improvement functional food composition for use.
상기 피부미백은 표피 세포를 구성하는 멜라닌형성 세포에서 생성된 멜라닌의 각질형성 세포로의 이동 억제; 및/또는 멜라닌형성 세포에서 멜라닌 생성 억제에 의한 것인, 피부 미백 및 광노화 개선용 기능성 식품 조성물.
7. The method of claim 6,
The skin whitening inhibits the movement of melanin produced in melanin forming cells constituting epidermal cells to keratinocytes; And / or by inhibiting melanin production in melanocytes, skin whitening and photoaging improvement functional food composition.
상기 멜라닌의 각질형성 세포로의 이동 억제는 이에 관여하는 Rab27A 및 MyosinVa의 발현 억제에 의한 것인, 피부 미백 및 광노화 개선용 기능성 식품 조성물.
9. The method of claim 8,
Inhibition of the movement of melanin into keratinocytes is by suppression of the expression of Rab27A and MyosinVa involved therein, a functional food composition for skin whitening and photoaging improvement.
상기 광노화 억제는 COX-2 (cyclooxygenase-2) 발현 억제에 의한 것인, 피부 미백 및 광노화 개선용 기능성 식품 조성물. 7. The method of claim 6,
The photoaging inhibition is by inhibition of COX-2 (cyclooxygenase-2) expression, skin whitening and functional food composition for improving photoaging.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190087333 | 2019-07-19 | ||
KR1020190087333 | 2019-07-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210010414A KR20210010414A (en) | 2021-01-27 |
KR102457475B1 true KR102457475B1 (en) | 2022-10-21 |
Family
ID=74238198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200089496A KR102457475B1 (en) | 2019-07-19 | 2020-07-20 | Cosmetic and functional food composition comprising caffeoylmalic acid having whitening and anti-photoaging activities |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102457475B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102572301B1 (en) | 2021-01-25 | 2023-08-30 | 현대모비스 주식회사 | Tear inducing apparatus for PAB door and manufacturing method thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100564935B1 (en) * | 2003-12-09 | 2006-03-30 | 학교법인 건국대학교 | method for manufacturing an edible film including water extract materials from canavalia gladiata and its pod |
KR101776071B1 (en) * | 2010-04-21 | 2017-09-07 | (주)아모레퍼시픽 | Composition containing red sword bean extract for anti-aging and whitening |
KR102577528B1 (en) * | 2015-08-28 | 2023-09-12 | 주식회사 엘지생활건강 | Composition for improving skin |
KR102371419B1 (en) * | 2017-06-12 | 2022-03-08 | (주)아모레퍼시픽 | Composition for skin whitening containing novel quercetin-based compound |
-
2020
- 2020-07-20 KR KR1020200089496A patent/KR102457475B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20210010414A (en) | 2021-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102124200B1 (en) | Cosmetic composition for antioxidation, skin-whitening and anti-wrinkle comprising fermented by-product of rice extracts its fractions as effective component | |
EP3354254B1 (en) | Skin whitening composition containing beta-mangostin as active ingredient | |
KR20120046064A (en) | Glucose-free pineapple extracts and methods for preparing thereof and their use | |
KR102457475B1 (en) | Cosmetic and functional food composition comprising caffeoylmalic acid having whitening and anti-photoaging activities | |
KR20200048158A (en) | Composition for antioxidant or improving skin wrinkle containing defatted Perilla frutescens extract | |
KR101236212B1 (en) | Cosmetic composition containing citrus natsudaidai extract for improving skin whitening | |
KR20120054375A (en) | Novel cosmetic composition having antioxidant activity or skin-whitening effect | |
KR101772494B1 (en) | COMPOSITION OF SKIN WHITENING CONTAINING EXTRACT OF Sargassum horneri AND METHOD OF MAKING THE SAME | |
KR101289813B1 (en) | Composition for anti-wrinkle comprising an extract of Sophora japonica L., Leguminosae | |
KR102301299B1 (en) | Skin-lightening Composition Using an Extract of Xanthium canadense | |
KR102090169B1 (en) | Cosmetic composition for anti-wrinkle and enhancing elasticity comprising fermented extract of Angelica tenuissima | |
KR101971257B1 (en) | A cosmetic composition comprising tenebrio molitor extract | |
KR20110069541A (en) | Skin-whitening composition containing lactone as an active ingredien | |
US20180353403A1 (en) | Skin-whitening cosmetic composition containing rosemary-derived verbenone as active ingredient | |
KR20160149499A (en) | Cosmetic composition and antioxidant composition comprising protein fraction extracted from orostachys japonicus as an active ingredient | |
KR20210073174A (en) | Methods for the preparation of nanoemulsion containing skin-whitening, anti-wrinkle and anti-inflammatory cosmetic composition and use thereof | |
JP6004599B2 (en) | Composition for improving skin condition comprising veratrmic acid or a salt thereof as an active ingredient | |
KR102600558B1 (en) | Composition for promoting hair growth and preventing hair loss comprising atraric acid | |
KR102488533B1 (en) | Preparing method of highly functional anti-inflammatory component drived from Glycine max Merr. fermentation extracts and cosmetic composition using the same | |
KR102329921B1 (en) | Composition for Improving Skin Conditions Extracts of Swallow's Nest Fermented by Novel Strain of Lactobacillus sp. as Active Ingredient | |
KR101534557B1 (en) | Skin-whitening composition containing Maackiasin thereof as an active ingredient | |
KR102498762B1 (en) | Composition for anti-wrinkle effect comprising fermented product of Momordica charantia or compound isolated from therefrom as effective component | |
KR102613802B1 (en) | Composition for skin whitening comprising culture of Lactobacillus reuteri and extract of Cnidium Monnieri | |
KR101795344B1 (en) | Cosmetic and functional food composition comprising gagunin D isolated from Phorbas sp. having whitening activities | |
KR102359044B1 (en) | Cosmetic composition for skin whitening comprising the color-flashed potatoes extract or fraction thereof as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |